top of page

About Us

Superior Disease Detection

We are addressing the tremendous, growing need for more reliable and sensitive diagnostic tests to accelerate drug development and enhance patient care. Our APEX technology is the first test that has demonstrated ability to detect – with a simple blood draw – low levels of the aggregated amyloid beta (Aβ) proteins that signal the presence of Alzheimer’s disease. APEX has significant promise for use in other neurological disorders as well.


Our pipeline of innovative, non-invasive technologies will empower researchers and clinicians with unparalleled insights not available from current tests. Our exceptional expertise in protein-based diagnostics positions us to become a global leader in the field, addressing significant research and clinical gaps, and serving multiple, sizable markets.

This important work and our team’s unwavering commitment to achieving our goals is driven by our values. At Sunbird Bio, we are:

  • Innovative: We are mission driven, unconventional thinkers and problem solvers, motivated by what could be.

  • Integrous: We are committed to doing what’s right, with humility and accountability to deliver trusted results to patients in need.

  • Resilient: We are agile and adaptable in our fast paced, dynamic world, demonstrating grit and perseverance daily.

  • Achieving More Together: We are a diverse team, unified by open communication, collaboration, continuous learning, and respect, creating a safe and supportive environment in which we may all thrive.

The 2023 Sunbird Bio merger with Glympse Bio brought together two leaders in the protein diagnostics field and provided additional technology, resources and know-how to drive paradigm-shifting success and improved patient outcomes.  

Learn more about our work in Alzheimer’s disease

bottom of page